Thromboembolic disease in surgery for malignancy - Rationale for prolonged thromboprophylaxis

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 6, 2002, Pages 569-576

  Khushal, Amjad ^a   Quinlan, Dan ^b   Alikhan, Raza ^a   Gardner, Jeremy ^a   Bailey, Clare ^a   Cohen, Ander ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cancer surgery; Deep vein thrombosis; Low molecular weight heparin (LMWH); Pulmonary embolism; Thromboprophylaxis

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ABDOMINAL SURGERY; ARTICLE; BLEEDING; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEMATOMA; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SKIN BRUISING; THROMBOEMBOLISM;

HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; ORTHOPEDIC PROCEDURES; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATIONS; SAFETY; THROMBOEMBOLISM; THROMBOLYTIC THERAPY;

EID: 12244256384     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36701     Document Type: Article

References (72)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S
2. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099-1103
3. Nicolaides AN, Bergqvist D, Hull R, et al. Prevention of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol 1997;16:3-38
4. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26:65-71
5. Rasmussen MS, Wille-Jørgensen P, Jørgensen LN. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg 1995;169:214-216
6. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992;127:310-313
7. Robinson KS, Anderson DR, Gross M, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med 1997;127:439-445
8. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-228
9. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700
10. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26-31
11. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998;89:281-287
12. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2208-2215
13. Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:853-861
14. Lausen I, Jensen R, Jørgensen LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: Randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998;164:657-663
15. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980
16. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-131
17. Sproul EE. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-585
18. Ambrus JL, Ambrus CM, Pickern J, Soldes S, Bross I. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 1975;6:433-458
19. Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999;25:239-243
20. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240-1245
21. Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982;96:556-560
22. Prandoni P, Lensing AW, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133
23. Griffin MR, Stanson AW, Brown ML, et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 1987;147:1907-1911
24. Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: An epidemiological study. BMJ 1994;308:891-894
25. Baron JA, Gridley G, Weiderpass E, Nyren O, Liner M. Venous thromboembolism and cancer. Lancet 1998;351:1077-1080
26. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-1173
27. Goldberg RJ, Seneff M, Gore JM, et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987;147:251-253
28. Trousseau A. Lectures on Clinical Medicine. London: The New Syndenham Society; 1872:282-332
29. Virchow R. Phlogose und Thrombose im GefäBsystem. In: Virchow R, ed. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. FrankFurt, Germany: von Meidinger Sohn; 1856:458
30. Moore FD Jr, Osteen RT, Karp DD, Steele G Jr, Wilson RE. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981;116:405-407
31. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407
32. Ogawa S, Gerlach H, Esposito C, et al. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest 1990;85:1090-1098
33. Patterson WP, Ringenberg QS. The pathophysiology of thrombosis in cancer. Semin Oncol 1990;17:140-146
34. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31
35. Booth BW, Weiss RB. Venous thrombosis during adjuvant chemotherapy. N Engl J Med 1981;305:170 (Letter)
36. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981;65:677-679
37. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-1268
38. Donati MB, Semeraro N. Cancer cell procoagulants and their pharmacological modulation. Haemostasis 1984;14:422-429
39. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988;48:3307-3312
40. Carty NJ, Taylor I, Roath OS, el-Baruni K, Francis JL. Tissue procoagulant activity may be important in sustaining metastatic tumour growth. Clin Exp Metastasis 1992;10:175-181
41. Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: An analysis of 1274 surgical patients. Br J Surg 1985;72:105-108
42. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: Analysis of the period from 1951 to 1988. Br J Surg 1991;78:849-852
43. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: Incidence, risk factors, and prophylaxis. Obstet Gynecol 1983;61:87-94
44. Clarke-Pearson DL, Synan IS, Coleman RE, Hinshaw W, Creasman WT. The natural history of postoperative venous thromboemboli in gynecologic oncology: A prospective study of 382 patients. Am J Obstet Gynecol 1984;148:1051-1054
45. Sørensen C, Andersen M, Kristiansen VB, Jensen R, Wille-Jørgensen P. The occurrence of late thromboembolic complications after elective abdominal surgery [in Danish]. Ugeskr Laeger 1990;152:1586-1587
46. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: A continuing problem. BMJ 1988;297:28
47. Kakkar VV, Corrigan TP, Fossard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975;2:45-51
48. Kiil J, Kiil J, Axelsen F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. Lancet 1978;1:1115-1116
49. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: A prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983;145:606-613
50. Wille-Jørgensen P, Kjaergaard J, Thorup J, et al. Heparin with and without dihydroergotamine in prevention of thromboembolic complications of major abdominal surgery. A randomized trial. Arch Surg 1983;118:926-928
51. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92-98
52. Bergqvist D, Lindblad B. The thromboprophylactic effect of graded elastic compression stockings in combination with dextran 70. Arch Surg 1984;119:1329-1331
53. Wille-Jørgensen P, Thorup J, Fischer A, Holst-Christensen J, Flamsholt R. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: A randomized trial. Br J Surg 1985;72:579-581
54. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989;62:1046-1049
55. Leizorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of logiparin and standard heparin. HBPM Research Group. Br J Surg 1991;78:412-416
56. Wille-Jørgensen P, Hauch O, Dimo B, et al. Prophylaxis of deep venous thrombosis after acute abdominal operation. Surg Gynecol Obstet 1991;172:44-48
57. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259-265
58. Collins R, Scrimgeour A, Yusuf S, Phil D, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-1173
59. Skinner JA, Gerrard DJ, Zahn H, et al. An assessment of deep venous function following total hip arthroplasty complicated by venographically proven deep vein thrombosis. Thromb Haemost 1995;73:1110
60. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
61. Andersen M, Wille-Jørgensen P. Late complications of asymptomatic deep venous thrombosis. Eur J Surg 1991;157:527-530
62. Cohen AT, Khushal A. Extended thromboprophylaxis following lower limb arthroplasty: What do the clinical trials mean? Haemostasis 2000;30:88-94
63. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med 1993;153:2221-2228
64. Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am 1997;79:319-325
65. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998;158:873-878
66. Cohen AT, Mohamed MS, Kakkar VV. The clinical experience of reviparin in the prevention of deep vein thrombosis. Drugs Today 1995;31:5-9
67. Paiement GD, Wessinger SJ, Hughes R, Harris WH. Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement. J Bone Joint Surg Am 1993;75:893-898
68. Cohen AT, Skinner JA, Kakkar VV. Antiplatelet treatment for thromboprophylaxis: A step forward or backwards? BMJ 1994;309:1213-1215
69. Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as post discharge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value in Health 2000;3:397-406
70. Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998;13:81-89
71. Sarasin FP, Bounameaux H. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. Arch Surg 1996;131:694-697
72. Friedman RJ, Dunsworth GA. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop 2000;370:171-182